Bausch + Lomb expects higher 2026 profit, but it replaced its CEO with an interim leader. No new figures were shared, leaving the positive expectation and leadership change balanced.
Appio’s earlier eye-care work gives him relevant experience. The company also expects a higher full-year profit measure. But it shared no new figures, and the increase still depends on final reviews. The sudden CEO handoff adds a separate concern. Together, the positive expectation and leadership change leave Bausch + Lomb’s business picture balanced.
Bausch Health’s operations outside Bausch + Lomb had 13 straight quarters of sales and adjusted profit growth, and the company expects higher 2026 profit. Appio’s added role and missing revised figures temper those signs but do not erase them.
Follow Bausch + Lomb Corp. (BLCO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BLCO